Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy acquires Biovel vaccine business

India's largest pharmaceutical company, Ranbaxy, has announced it is to acquire the product rights and manufacturing facility of Biovel Lifesciences

India's largest pharmaceutical company, Ranbaxy, has announced it is to acquire the product rights and manufacturing facility of Biovel Lifesciences. The value of the deal was not disclosed.

The transaction will provide Ranbaxy with access to all of Biovel's products (including the Typhoid Vi antigen and Hib conjugate vaccines, for which Biovel has received regulatory approval for India), intellectual property and its pipeline, along with a manufacturing facility in Bangalore, India.

Ranbaxy's CEO and MD, Atul Sobti, said: "With an increasing focus on prevention of disease, the importance of the vaccine market has never been greater. This transaction with Biovel provides us an entry platform to manufacture vaccines as well as biotherapeutics. The vaccine and biotherapeutics business will be an important part of our growth strategy."

According to Ranbaxy, the Indian vaccine market is growing at 10 per cent per annum – 1 per cent higher than the global rate. The global vaccines market is predicted to reach $34bn by 2014.

20th January 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...